Cytokinetics, Incorporated — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Cytokinetics is a late-stage biopharmaceutical company developing muscle-function therapies. It has not generated revenue from commercial product sales.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / prior year-end |
|---|---|---|
| Total revenue | $4.6 million | $1.1 million |
| Research and development expense | $79.4 million | $45.9 million |
| General and administrative expense | $49.7 million | $33.1 million |
| Operating loss | $124.5 million | $77.9 million |
| Net loss / diluted loss per share | $131.3 million / $1.38 | $89.4 million / $1.05 |
| Net cash used in operations | $122.3 million | $26.8 million |
| Cash, cash equivalents and investments | $704.4 million | $829.3 million at Dec. 31, 2022 |
| Working capital | $605.4 million | $710.6 million at Dec. 31, 2022 |
| Total borrowings, net carrying value | $610.6 million | $609.6 million at Dec. 31, 2022 |
Revenue included $2.1 million of research and development reimbursements, primarily from Astellas, and a $2.5 million aficamten milestone from Ji Xing. Operating expenses substantially exceeded revenue; product margins are not meaningful because there are no commercial product sales. Total liabilities were $1.12 billion, exceeding total assets of $889.8 million; stockholders’ deficit was $229.0 million. Cash flow from investing activities was positive $165.5 million, mainly reflecting investment maturities and sales, while financing activities used $7.2 million. Q1 cash use is not necessarily a run-rate forecast.
Material changes and notable developments
- Revenue rose $3.5 million year over year, but R&D expense increased $33.5 million and G&A expense increased $16.6 million. The larger expense base drove a wider operating and net loss.
- On February 28, 2023, FDA issued a Complete Response Letter for omecamtiv mecarbil, finding GALACTIC-HF insufficiently persuasive and requiring an additional clinical trial. Cytokinetics said it had no plans to conduct that trial. The CRL also made $75 million of conditional RP loan tranches unavailable; $175 million in later aficamten-linked tranches remained conditionally available.
- On March 31, 2023, the company announced discontinuation of the Phase 3 COURAGE-ALS trial and its open-label extension after a futility review found no evidence of benefit on the primary or key secondary endpoints.
- Aficamten remained the principal development focus. SEQUOIA-HCM had enrolled more than two-thirds of its planned 270 patients, with topline results expected in Q4 2023; MAPLE-HCM was expected to start in Q2 2023. Positive Cohort 4 REDWOOD-HCM and 48-week FOREST-HCM results were reported, but these are clinical findings and do not establish approval or commercial success.
Outlook, risks and financing
Management stated that existing cash, cash equivalents and investments were expected to fund projected cash requirements for at least 12 months after filing. It also anticipated continued operating losses and cash outflows and may need additional collaboration, equity or debt financing. The filing refers to 2023 revenue and net-cash-use guidance, but the provided filing text does not give clear numeric guidance.
The company established a $300 million at-the-market equity facility in March 2023, which may provide financing but could dilute shareholders. It also reported $306.8 million of liabilities related to royalty-purchase arrangements; royalty payments and related non-cash interest depend on commercialization forecasts and other estimates. Key risks include clinical-trial and regulatory outcomes, aficamten enrollment and results, financing availability, execution by partners and vendors, and future market access and reimbursement. Management reported disclosure controls were effective at the reasonable-assurance level and no material legal proceedings were disclosed.
Most important facts for investors to verify
- Progress, enrollment and timing of SEQUOIA-HCM and MAPLE-HCM, and whether the anticipated results and trial start dates are achieved.
- FDA follow-up on the omecamtiv mecarbil CRL, and the status of the EMA review and Ji Xing’s China/Taiwan application.
- Cash burn relative to the stated 12-month runway, access to conditional Royalty Pharma funding, and any use of the ATM facility.
- Updated development and commercialization assumptions underlying the royalty liabilities and potential future royalty payments.
- Whether discontinuation of COURAGE-ALS changes costs, Astellas reimbursements, or the company’s broader R&D plans.